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policies, the availability of essential genomic tests which dif-
fers between various countries owing to differences in dis-
ease prevalence and public health relevance, the prescribing 
and use of genomic testing services according to existing or 
new guidelines, budgetary and fiscal control, the balance 
between price and access to innovative testing, monitoring 
and evaluation for cost-effectiveness and safety, and the de-
velopment of research capacity. We conclude that address-
ing the specific items put forward in this article will help to 
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 Abstract 
 This paper aims to provide an overview of the rationale and 
basic principles guiding the governance of genomic testing 
services, to clarify their objectives, and allocate and define 
responsibilities among stakeholders in a health-care system, 
with a special focus on the EU countries. Particular attention 
is paid to issues pertaining to pricing and reimbursement 
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create a robust policy in relation to pricing and reimburse-
ment in genomic medicine. This will contribute to an effec-
tive and sustainable health-care system and will prove ben-
eficial to the economy at large.  © 2016 S. Karger AG, Basel 
 Introduction 
 At a time of unprecedented technological advance-
ment, genomic medicine (an important part of personal-
ized and precision medicine strategies) holds out the 
promise to detect the onset of disease, ideally at its earli-
est stages, either presymptomatically or through the de-
termination of individual risk, in an effort to forestall 
(prevent) the progression of disease and to individualize 
drug treatment modalities. At present, this can be per-
formed in a handful of cancers, in monogenic disorders 
such as the hemoglobinopathies and cystic fibrosis etc., 
and for over 100 drug treatment modalities  [1] . Genom-
ic medicine aims to improve the shared medical deci-
sion-making process and to rationalize drug prescription 
for the benefit of both the patient and the national health-
care system, by taking advantage of an individual’s 
unique genetic/genomic profile. Genomic medicine has 
the potential to (a) shift the emphasis in medicine from 
clinical/therapeutic intervention to prevention, (b) di-
rect and/or inform the selection of optimal therapies and 
reduce trial-and-error prescribing, (c) help to avoid ad-
verse drug reactions, (d) improve quality of life, (e) reveal 
additional or alternative uses for medicines and drug 
candidates and help in the selection/design of novel ther-
apeutics or therapeutic regimes (re-tasking), and (f) aid 
in containing the overall cost of health care in the me-
dium to long term  [2] .
 Genomic medicine also promises to improve the qual-
ity of clinical care, while ideally lowering health-care 
costs. Although scientific challenges still remain and both 
the cost and time required to perform genome sequenc-
ing continues to drop, the economic issues and policy 
making still present a serious hurdle  [3] . The decision to 
introduce genomic medicine into the public health-care 
system is dependent upon a range of factors and will re-
quire the combined efforts of multiple stakeholders in so-
ciety (innovators, research organizations and academic 
centers, entrepreneurs, funders and payers, citizens, both 
healthy individuals and patients, regulators, policymak-
ers, and legislators). It would appear that many key stake-
holders are generally favorable to the implementation of 
genomic medicine  [4–6] . However, all necessary policies 
and measures should be implemented to foster the overall 
positive attitude of most stakeholders towards genomic 
medicine, while at the same time ensuring that genomic 
medicine is implemented in an efficient and effective 
manner that upholds the spirit of solidarity in health-care 
systems in most countries. If this is done, then the re-
maining stakeholders, who might hold a neutral-to-neg-
ative opinion, will also be content and supportive  [3] .
 The most important factors required for the successful 
implementation of genomic medicine into the public 
health-care system are: (a) affordability, (b) acceptability, 
fairness, solidarity and appropriateness, (c) appropriate 
knowledge and education (for clinicians and patients) 
available, (d) political engagement and willingness to 
change existing health care, (e) appropriate policy and 
legislation, (f) demonstration of proven and undisputed 
clinical efficacy, and (g) of demonstrated cost-effective-
ness  [7–9] . If payers are unwilling to reimburse the costs 
of genomic testing services, progress towards incorpora-
tion and implementation will be stalled. Reimbursement 
decisions in relation to genomic testing are complicated, 
and although genomic testing has been performed for 
more than 20 years, the respective decision-making pro-
cess is still evolving  [10, 11] .
 In the United States, the Centers for Medicare and 
Medicaid Services (CMS) manage the Clinical Laboratory 
Improvement Amendments (CLIA) program, which in-
spects and regulates clinical laboratories, including those 
performing genomic testing  [12–14] . Several US govern-
ment agencies are currently working towards the devel-
opment of regulatory standards for genomic testing labo-
ratories and the comprehensive integration of genomic 
testing into routine medical practice. The Centers for 
Disease Control and Prevention has an advisory group 
specifically focused on the CLIA regulations (Centers for 
Disease Control: Genetic Testing Policy), as well as proj-
ects studying the validation of genomic tests and the in-
tegration of these tests into clinical practice (Centers for 
Disease Control – Genetic Testing). In addition, the Sec-
retary’s Advisory Committee on Genetics, Health and
Society (SACGHS) issued a comprehensive report sum-
marizing the issues surrounding the reimbursement of 
genomic tests (see: Coverage and Reimbursement of Ge-
netic Tests and Services)  [9, 15] . The National Human 
Genome Research Institute (NHGRI) hopes to serve as a 
resource for advancing genomic medicine by assisting all 
types of payers in their efforts to evaluate emerging ge-
nomic tests for reimbursement, and by promoting re-
search into the health benefits and cost-effectiveness of 
genomic testing  [16] .
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 In the EU, the regulatory structure for the reimburse-
ment of medical devices differs from country to country 
(recent regulations brought in in vitro diagnostics that 
require stricter clinical evidence). In Germany, it is ad-
ministered by Der Gemeinsame Bundesausschuss (G-
BA), in France by La Haute Autorité de Santé (HAS), in 
the UK by the National Health Service (NHS), in Italy by 
Il Servizio Sanitario Nazionale (SSN) and in Spain by El 
Instituto Nacional de la Salud (INS). Consequently, the 
health-care procedure reimbursement structure for Eu-
ropean nations also differs from country to country due 
to differences in health-care budgets, health-care policies, 
etc.  [17] . However, all EU countries follow the EU direc-
tive on medical device regulations. Within this directive, 
a medical device must have the Conformité Européenne 
(CE) mark to be sold within the respective member coun-
tries denoting some sort of EU harmonization  [12–14] . 
However, this is not the only prerequisite for a device to 
be sold in the EU since many member states have also ad-
opted complex reimbursement policies (requiring the de-
vice to be included in an approved reimbursement list of 
diagnostic amenities).
 Coverage, Pricing and Reimbursement Strategies for 
Genomic Tests 
 The reimbursement structures in the United States 
and European countries are influenced by spiraling 
health-care costs, increasing patient waiting times, and 
deficit financing for their burgeoning health-care expen-
diture. This has led to restrictions in the amounts public 
payers or managed care organizations are reimbursing, 
with respect to expensive new genomic tests and molecu-
lar diagnostic procedures.
 While cost-effectiveness may or may not be considered 
by payers in their decision-making process relating to 
these high-value tests, the impact of direct cost savings is 
important for some payers, particularly in relation to the 
use of these tests in the context of the avoidance of inap-
propriate or unsafe drug therapy  [12–14, 17] . However, 
the EU’s reimbursement environment is not uniform 
since each member state has its own policies, with reim-
bursement being approved by either private or public in-
surance companies or a combination of the two. Approv-
al for reimbursement from public health providers often 
requires lengthy negotiations. The potential differences 
across member states are compounded by the problem of 
centralized versus decentralized national systems, includ-
ing the tendency of most EU nations to review/authorize 
tests at the local level. This local approach to coverage and 
reimbursement assessment of genomic testing, compared 
with national level reviews for most drugs, can present 
substantial barriers to consistent market access for ge-
nomic/pharmacogenomic tests and services  [12–14] .
 Product pricing also displays marked differences due to 
various factors such as supply-demand fluctuations, differ-
ences in various government tax rates (for example VAT, 
customs) etc. Thus, France has reduced the rate of VAT 
payable on medical devices, whereas other countries in-
cluding Germany have maintained the maximum rate of 
VAT. Moreover, there are differences in health technology 
assessment (HTA) systems both between and within coun-
tries that would benefit from standardization; at present, 
there is no precedent for value capture, as the future regu-
latory framework for high-risk tests, including those used 
in genomic medicine, is likely to evolve  [18, 19] .
 Components of the Proposed Strategy for Pricing 
and Reimbursement 
 The ideal strategy for pricing and reimbursement in 
genomic medicine should incorporate the following ob-
jectives ( fig. 1 ):
 1 Universal access to essential genomic testing for all, 
and at acceptable prices for the health-care system
 2 Sufficient regulation to ensure safety, efficacy, quality, 
fairness and solidarity, while allowing space for inno-
vation necessary to move the field forward
 3 Appropriate use of genomic tests and information by 
physicians, according to patients’ needs and clinical 
utility/action ability of testing outcomes
 4 Investment in both human resources and capital for 
the research into the field of genomic medicine, evalu-
ation of novel and existing diagnostic procedures, and 
monitoring of patient safety
 These objectives are discussed in detail below from the 
perspective of the European Union, although most of the 
principles presented will have applicability to decision 
makers in other systems.
 Universal Access to Essential Genomic Testing for All, 
at Acceptable Prices for the Health System 
 By definition, essential genomic tests are those tests 
that satisfy the priority health-care needs of a given popu-
lation. Essential genomic tests, like essential medicines, 
are selected with due regard to disease prevalence and 
public health relevance, evidence of clinical efficacy and 
safety, and comparative costs and cost-effectiveness.
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 Availability 
 Ideally, the availability of genetic testing should be the 
right of all residents (insured or not/not tied to citizenship, 
as applied in the EU countries) to ensure the safe use of 
medication and should be: (a) made available in a timely 
manner, (b) distributed according to therapeutic need, and 
(c) accessible irrespective of locality, age, gender or income. 
Fulfillment of these prerogatives (along with supporting 
clinicians and patients to promote good decision making) 
will lead to greater health and patient safety, as well as great-
er efficiency and sustainability of genomic medicine and of 
health systems. Currently, genomic tests may be prescribed 
on the basis of the patients’ ability to pay, rather than need, 
therapeutic rationale or cost-effectiveness  [20] . This policy 
proposal addresses the problems of high out-of-pocket 
payments and expenditure, and deviation from interna-
tional standards of care and equitable access.
 In order to avoid high out-of-pocket payments, it is 
first necessary to select the essential genomic tests that 
would be made available and reimbursed under the posi-
tive medical devices’ list. Driven, kept relevant and regu-
larly updated by clinical guidelines, this process would 
contribute to a more rational prescribing regime (as was 
the case with drug prescription), less confusion and great-
er familiarity with genomic testing amongst diagnostic 
laboratories and providers. On the whole, the develop-
ment of a positive medical devices’ list should lead to bet-
ter health outcomes with cost containment in both the 
medium and long term  [21] . As will be described later, the 
classification of every genomic test should be document-
ed by cost-effectiveness analyses with provisions to use 
HTAs in the decision-making process.
 The key stakeholders tasked with ensuring the avail-
ability and affordability of genomic tests are the Minis-
tries of Health, regulatory bodies, payer organizations, 
medical device manufacturers, wholesalers, academic 
and other research institutes, pharmaceutical companies, 
pharmacies, hospitals and clinics, public and private di-
agnostic laboratories and physicians  [22] . The European 
Parliament Directives (in the next few years, they will be 
changed to regulations so as to avoid different national 
interpretations) set the rules on marketing authoriza-
tions, as well as on advertising, product quality and safe-
ty, and labeling regulations. These policies complement 
those already made at the national level, and especially 
those outlined in our policy proposal, with regard to pric-
ing, access, research, and monitoring.
 Affordability 
 Affordable prices are crucial to ensuring that the pop-
ulation as a whole has access to essential genomic tests. 
Increasing affordability should be a key commitment of 
government to guarantee that pecuniary issues do not 
constitute barriers to people’s access to genomic testing. 
The government and regulatory bodies should address 
the affordability of essential genomic tests, such as phar-
macogenomic tests, as a policy concern in the context of 
both pricing and reimbursement.
 Only an effective, transparent, sustainable and robust 
pricing system can guarantee affordable prices and hence 
access to genomic tests for the entire population. Under 
such an arrangement, the pricing of genomic tests is ac-
complished through merit and supply and demand, 
which ensures that pricing decisions take into account the 
 Fig. 1. The framework of the sequence of 
stages a new genomic (companion) diag-
nostic test has to pass before a citizen-pa-
tient may obtain access to it. 
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comparative effectiveness of new genomic tests and their 
incremental effects relative to their incremental costs, as 
components of a cost-effectiveness analysis. The pricing 
process should be transparent, and all stakeholders should 
have access to all the relevant information that was used 
to determine prices, most likely through negotiation un-
der a comprehensive HTA process. Each country’s Med-
ical Devices regulatory authority or HTA Agency needs 
to build capacity in terms of infrastructure, skills and ex-
pertise to be able to fulfill the task of determining the ap-
propriate pricing of genomic tests and to take a strong 
stand in disputes with manufacturers or representatives 
over the determination of prices, always recognizing the 
complications and bottlenecks of the existing system.
 The pricing system should ensure that, while compet-
itive market rules are not violated, public and private pay-
ers and insurers are protected from excessive expenditure 
that could act as a barrier to patient access, such as high 
out-of-pocket payments. Pricing policies should aim to 
reduce monopoly power granted to manufacturers in or-
der to contain costs in the diagnostic market. The pricing 
system should support a sustainable environment for 
such products that achieves an optimal mix between 
health and commercial policy. Cost containment mea-
sures should reflect these priorities and the development 
of a sound policy should take precedence over price regu-
latory measures to achieve the goal of long-term sustain-
ability of the health-care system.
 An effective, transparent and sustainable reimburse-
ment system for all clinical products guarantees reason-
able cost sharing for the population, while ensuring their 
access to these tests and services. Adequate levels of co-
payments (which are paid in part by the patients/citizens 
themselves) and co-insurance ensure that cost and ex-
penditure reduction goals are met in every country while 
not compromising patient access in terms of affordabili-
ty. The criteria of genomic test classification for the posi-
tive list, including essential genomic tests by default, 
should be carefully controlled and regularly reviewed, es-
pecially in relation to the emergence of clinical, econom-
ic, fiscal or other criteria, and how these different criteria 
should be weighed against each other in the decision-
making process. Price bulletins should be issued in order 
to keep stakeholders informed of price fluctuations. In 
addition, a negative list (like those already in place in sev-
eral countries) of genomic tests should also be developed 
to include those genomic tests that fail to meet certain 
scientific standards, such as is currently the case with nu-
trigenomic testing, as well as tests that aim to determine 
athletic performance, intelligence criminality, personali-
ty, genomic identity testing, etc.  [23–25] . For such tests, 
no co-payments should be allowed, whether through 
public or private insurance schemes; out-of-pocket pay-
ments should be the only means to purchase them.
 It is also of the utmost importance that government 
remains committed to the public financing of health ser-
vices. At present, a course of privatization and market 
shift is becoming increasingly apparent even in those Eu-
ropean countries traditionally oriented toward public 
health care provision (e.g. France, UK, Czech Republic 
and latterly Greece). Given that in most cases, public 
health resources are limited, it is necessary to carefully 
(re)define government policy and select priorities for 
public funding on that basis. The establishment of an 
HTA agency could also contribute to the selection of pri-
ority areas for the allocation of limited public health 
funds.
 A first action would be to set up a pricing committee 
within a country’s HTA Agency, that would oversee the 
pricing of all genomic tests which are in strict adherence 
to EU (or other area) legislation (though some argue that 
pricing needs to be based on competition and market 
rather than committees). Although organized within the 
country’s medical devices regulatory authority or HTA 
agency, the pricing committee should have a sufficient 
number of qualified members of staff to conduct back-
ground checks and maintain databases in order to advise 
appropriate prices for all new (or existing) genomic tests 
entering the market, aiming to allow reimbursement by 
public insurance funds. The committee should fulfill its 
role in a timely fashion and in a robust way. To achieve 
these goals, it will be necessary to define the committee’s 
terms of reference, member composition, including as-
sessment of necessary content expertise, governance, 
lines of accountability, and support by a secretariat, which 
would include in-house capacity for data searching, da-
tabase maintenance, and cooperation with the stake-
holders. The pricing committee, just as in the case of 
medicines, should also participate in pharmaceutical and 
medical devices policy cooperation EU committees (or 
forums) in order to ensure that the committee has access 
to information about ongoing and planned activities in 
the field of pricing policy at community level while adher-
ing to the transparency directive.
 Another key step would be to merge all currently exist-
ing committees that are involved in the reimbursement 
process under the umbrella of a positive list and reim-
bursement committee. This committee would oversee ge-
nomic test reimbursement in order to reform the usually 
highly fragmented system that is currently in place in 
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many countries. The reimbursement committee would 
need to act according to a governance structure with rules 
pertaining to responsibility and accountability that would 
have to be clearly defined.
 With respect to specific genomic tests, hospitals and 
the Public Insurance Funds/Payers might employ a ten-
dering system to promote price competition between 
manufacturers or, most importantly, distributors. How-
ever, this method of procurement has sometimes been 
associated with delays in patient access, as companies that 
have lost out in tendering have reacted by contesting the 
award of a contract. While tendering remains a viable sys-
tem for pricing and procurement of genomic tests, the 
current system must be streamlined and made more 
transparent. To be sustainable, this process must be re-
peated fairly regularly, ideally on an annual (or biennial) 
basis, depending on the innovation stepping.
 Proposed Actions for Objective 1 
 1 Expand the range of evidence-based clinical guidelines 
(prescribing recommendations) taking into account 
international standards. These must be an integral part 
of the e-prescribing module of a national health infor-
mation system.
 Relevant stakeholders: National medicine agency, the 
medical devices regulatory authority or HTA agency, 
positive list committee, public insurance funds/payers 
physicians, international partners.
 2 Set up a pricing advisory committee within the HTA 
Agency that would oversee the pricing of all new or 
existing genomic tests with strict adherence to EU (or 
other area) legislation.
 Relevant stakeholders: The medical devices regulatory 
authority or HTA agency, public insurance funds/payers, 
ministry of health, patient representatives.
 3 Merge all currently existing reimbursement commit-
tees under the umbrella of a positive list and reim-
bursement committee.
 Relevant stakeholders: The medical devices regulatory 
authority or HTA agency, ministry of health.
 4 Streamline and make transparent the procurement 
and pricing processes in order to avoid launch delays 
of innovative tests.
 Relevant stakeholders: The medical devices regulatory 
authority or HTA agency, public insurance funds/payers, 
medical devices industry, wholesalers and private phar-
macies, genetic laboratories.
 5 Revise the current positive list to align with treatment 
protocols in order to rationalize procurement of inno-
vative genomic tests.
 Relevant stakeholders: The medical devices regulatory 
authority or HTA agency, public insurance funds/payers, 
medical devices industry.
 6 Develop, implement and enforce expeditious and 
transparent tendering and review processes for spe-
cific genomic tests.
 Relevant stakeholders: The medical devices regulatory 
authority or HTA agency, public insurance funds/payers, 
medical devices industry.
 7 Maintain government commitment to public financ-
ing of health services.
 Relevant stakeholders: Ministry of health, public insur-
ance funds/payers.
 Sufficient Regulation to Ensure Safety, Efficacy, 
Quality, Fairness, and Solidarity, while Allowing 
Space for Innovation Necessary to Move the Field 
Forward 
 Robust regulation is a key parameter to ensure test 
safety, efficacy and quality and should be a product of 
strong cooperation between all relevant stakeholders. 
Quality assurance is the responsibility of all the stake-
holders involved in the medical device supply chain, al-
beit in different ways. Manufacturers are responsible for 
developing and manufacturing good quality products 
and adhering to good manufacturing practice. The medi-
cal devices regulatory authority must ensure that tests ap-
proved for prescribing (and reimbursement) are first 
evaluated and registered appropriately, that manufactur-
ers comply through licensing and inspection and that the 
test quality is ensured and maintained in the supply sys-
tem. This includes the assessment of good storage and 
distribution practices in addition to continual monitor-
ing of the quality of testing devices and procedures in the 
distribution chain. Procurement agencies should ensure 
that genomic tests are selected carefully, purchased from 
reliable sources, namely distributors and/or wholesalers, 
inspected at the time of delivery, and stored and trans-
ported appropriately.
 Safety assurance is the second key consideration for 
regulatory bodies. Safety is reviewed during the market 
approval and registration process, but postmarketing 
monitoring has to be in place to reliably record and assess 
adverse reactions. In the EU, it is the EU Medical Device 
Vigilance System that collects and manages data on the 
safety of medicines and uses them to make decisions with 
regard to safety issues  [26] . A similar process must also be 
put in place for genomic testing services, to address issues 
pertaining to accuracy and/or testing reliability.
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 While regulation for quality and safety is important, it 
must also be recognized that in a rapidly changing field 
such as genomics, traditional approaches to regulation 
may not be able to respond quickly enough to the chang-
ing evidence. This has the potential to impede innovation 
 [27] . Therefore, careful attention must be paid to balanc-
ing regulations to assure quality and safety while preserv-
ing the opportunity for innovation.
 Regulatory decisions therefore result from substan-
tial cooperation and consultation among all the relevant 
stakeholders in the medical device market, particularly 
in relation to the timely implementation and monitor-
ing of the relevant provisions. Manufacturers are re-
sponsible for providing high-quality products, whereas 
physicians play a key role in following medical guide-
lines that ensure appropriate prescribing. Government 
institutions and regulators are responsible for the pro-
motion of cooperation among all the stakeholders and 
the involvement of these parties in the decision-making 
process.
 Actions for Objective 2 
 1 Quality assurance has to be the responsibility of all the 
stakeholders in the supply chain.
 Relevant stakeholders: Medical devices industry, min-
istry of health, public insurance funds/payers, quality as-
surance organizations, physicians, pharmacists, whole-
salers, and all the regulatory bodies.
 2 Adherence to the EU Medical Device Vigilance System 
needs to be enforced.
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, ministry of 
health and all the regulatory bodies.
 3 Regulatory decisions need to build on substantial co-
operation between all the stakeholders.
 Relevant stakeholders: The medical devices regulatory 
authority, ministry of health, public insurance funds/pay-
ers, all the regulatory bodies, physicians, the medical de-
vices industry, wholesalers, and pharmacists.
 Appropriate Use of Genomic Tests and Information by 
Physicians, according to Patients’ Needs and Clinical 
Utility/Actionability of Genomic Testing Outcomes 
 Physicians have the responsibility for prescribing ge-
nomic tests rationally, ensuring appropriate, adequate 
and cost-effective care, while informed and empowered 
patients should play an equally important role based on 
their personal circumstances and preferences. Prescrib-
ing genomic tests rationally requires the provision of best 
practice recommendations and relevant information to 
physicians. A continued expansion, enhancement and le-
veraging of the e-prescribing systems (see next para-
graph) is essential for more effective, efficient, and appro-
priate prescribing of tests to all citizens, e.g. as a screening 
policy for high-risk citizens. This system will monitor 
physicians’ prescribing, providers’ implementation and 
pharmacists’ distribution records in order to rationalize 
the provision of genomic tests  [28] . A good example is the 
use of disease-specific ‘Clinical Utility Gene Cards’ which 
establish a priori peer-reviewed criteria for indication of 
genomic testing  [29] . Another issue which needs to be 
dealt with is the uncontrolled indication of cross-border 
genomic testing  [30] .
 The health-care industry is witnessing an increased 
adoption of e-prescribing systems due to the pressing 
need to curtail health-care costs, while maintaining the 
quality of care provided to patients and reduce medica-
tion errors and adverse drug events. The market is also 
witnessing a growing demand for integrated e-prescrip-
tion systems, facilitating the health-care community to 
shift towards the implementation of a complete electron-
ic health record system  [31] .
 Important measures for rational use from the side of 
suppliers are the prescribing of genomic tests on the basis 
of international classification (coding) and their provi-
sion to citizens-patients according to existing guidelines. 
The former depends critically upon physicians’ access to 
standardized prescribing protocols across therapeutic 
categories. Physicians and patients must work together to 
understand the treatment and the diagnostic options 
available. Therefore, evidence-based medicine must be 
provided to patients at the level of the physician and the 
pharmacist.
 Actions for Objective 3 
 1 Expand and continuously update the e-prescribing 
system; integrate this IT database with patient record 
databases currently existing (or in development).
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, ministry of 
health and all the regulatory bodies, physicians, pharma-
cists, and international partners.
 2 Prescriptions made according to international pre-
scribing protocols, with a view to engaging in interna-
tional coding-based prescribing.
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, physicians, and 
international partners.
 3 Educate clinicians with respect to the favorable use of 
evidence-based (in terms of safety and efficacy) medi-
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cine to meeting patient’s needs; foster collaborative 
doctor-patient relationships in order to make pre-
scribing more efficient.
 Relevant stakeholders: Physicians, pharmacists, pa-
tients.
 Investment in Both Human Resources and Capital 
for Research into the Field of Genomic Medicine, 
Evaluation of Novel and Existing Diagnostic 
Procedures, and Monitoring of Patient Safety 
 Investments in human capital and infrastructure are 
key components to promote research in the field of ge-
nomic medicine, evaluate novel and existing diagnostic 
procedures, and monitor patient safety to promote effec-
tive patient care, affordability of the health-care system 
and profitability for the industry. Research is a critical 
component for health-care systems in order to allocate 
resources appropriately and evaluate performance opti-
mally. It is especially necessary for the genomic medicine 
sector, which has the added requirement of sufficient 
R&D investment for newer, innovative approaches and 
products. Thus, research not only has the potential to 
make savings and recoup expenditure, thereby making 
efficiency gains for the health sector, but also to contrib-
ute to the economy as a whole through the development 
of patentable technologies.
 Investment in R&D is partly a function of the health-
care system, of the national priorities for health-care re-
search and of a whole host of factors, both financial and 
nonfinancial, that define national policy. Significant re-
search investments are made by manufacturers, and this 
may be encouraged through both industrial and health 
policy. A national policy platform may help to encourage 
investment in R&D, for example by promoting a more 
flexible and responsive regulatory framework to attract 
clinical trials.
 Rational use of resources relies upon the availability of 
clinical cost-effectiveness or cost-benefit or relative effec-
tiveness data. HTA activities can contribute significantly 
in this direction, for example by (a) contributing to the 
making and updating of positive, negative and high-cost 
lists of genomic tests by the payers, (b) helping to divert 
public health funding from less cost-effective services to-
wards diagnostic tests and pharmacotherapies with great-
er diagnostic, prognostic and therapeutic values, respec-
tively, (c) specifying clinical and prescribing protocols 
based on clinical cost-effectiveness criteria, and (d) ad-
vancing e-health systems.
 Actions for Objective 4 
 1 Identify and address gaps in the regulatory framework 
that will help to attract R&D investment.
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, ministry of 
health, pharmaceutical companies, medical associations, 
other government departments.
 2 Examine the scope for the identification of priorities 
for health research and the creation of a national plat-
form for the same.
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, ministry of 
health, academic institutions, other government depart-
ments.
 3 Actively pursue the use of HTA to conduct cost-effec-
tiveness or cost-benefit or relative effectiveness analy-
ses for more informed decision-making on genomic 
testing cost reimbursement.
 Relevant stakeholders: The medical devices regulatory 
authority, public insurance funds/payers, domestic and 
international academics/experts.
 4 Physicians should utilize their clinical expertise to as-
sist/contribute in the creation and adoption of clinical 
guidelines and corresponding prescribing protocols, 
to be integrated into the e-health system.
 Relevant stakeholders: Public insurance funds/payers, 
physicians, ministry of health.
 Public Policy Concerns 
 Funding and Pricing of Highly Innovative Genomic 
Tests 
 Although lower prices may emerge from the develop-
ment of increasingly efficient and widespread technolo-
gies, it is crucial that reimbursement levels, which have 
been set unilaterally by policymakers in most European 
countries will not only ensure massive access to high 
quality tests but also continue to allow for the develop-
ment of a pipeline of innovative tests that require sub-
stantial risk-based research (defined as the uncertainty of 
the investment in innovation). Many genomic tests, par-
ticularly those complex predictive tests that require pro-
spective clinical trials, are not funded or reimbursed ap-
propriately. Such lack of funding and reimbursement
inevitably tends to inhibit access, as laboratories are in-
centivized to offer those tests that are better reimbursed 
and are most reluctant to offer tests that might be unprof-
itable; the unfortunate consequence of this is that some 
treatment pathways may not be appropriately explored 
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with personalized diagnostic information. Although this 
may present some hurdles for the private sector, regula-
tion and EU harmonization are still required so as to min-
imize the impact of the ‘free-market’ shortcomings in the 
health-care sector. Moreover, the opacity of the current 
reimbursement environment acts as a disincentive to re-
search and development investment in innovative diag-
nostics and, by extension, diagnostic-therapeutic combi-
nations  [32] . As noted above, the regulatory framework 
must also be sufficiently flexible to manage the rapidly 
changing environment while not stifling innovation  [27] . 
Generally, funding can either be provided by the health-
care system, or by a medical device company or by the 
patients ( fig. 2 ).
 Recommendation: HTA processes within a country 
should be coordinated in a way that allows a single inte-
grated HTA report for diagnostic companion products.
 Reason: Genomic diagnostics have no direct health 
improvement effect but potentially generate downstream 
health effects when used as indicated to inform therapeu-
tic options  [26] . Making wise policy decisions in this area 
is the single biggest challenge for all stakeholders.
 Evaluating Diagnostic, Prognostic, and Predictive 
Genomic Tests 
 HTAs represent a rapidly growing area of European 
government policy, and one which has accelerated over 
the last few years as governments seek to contain costs. 
However, most of the paradigms for health care appraisal 
and technology assessment have been developed for the 
purpose of comparing procedures or drug therapies. To-
day, tests are evaluated in the context of a much broader 
concept of their ‘clinical utility’, namely cost-effective-
ness, budget impact, priorities, etc. Although most people 
would agree that genomic tests are beneficial by having 
an impact both on patient management and the delivery 
of treatments, many are still concerned that processes un-
derlying ‘clinical utility’ assessments are neither clear nor 
predictable. More objective and reliable standards for 
these evaluation processes need to become broadly ac-
cepted. Since many argue that reimbursement should be 
tied to value, ‘ value ’ (i.e. utility for the patient, economies 
for the payer) needs to be acceptably defined, taking into 
consideration how difficult it has been to consider all fac-
tors involved in ‘ value ’ and to implement value-based 
pricing  [33] .
 Quality can be improved by employing quality assur-
ance measures ( fig. 3 ). The meaning of different quality 
endorsements is often confusing  [34, 35] :
 Recommendation: All laboratories performing ge-
nomic diagnostic tests should be required to be accred-
ited, and existing external quality assessment schemes 
should be extended both at National and International 
levels.
 Reason: Improving genomic testing quality reduces 
the number of misclassifications, such as incorrect test 
results. Misclassifications cannot benefit from a treat-
ment diagnosis or who may even be at risk of harm by it 
being treated nonetheless. Accreditation is the most ex-
tensive quality endorsement, covering test quality inside 
 Fig. 2. Potential funding sources and mech-
anisms for genomic (companion) diagnos-
tics. DRG = Diagnosis-related groups. 
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the laboratory and at the interface with clinicians. Ac-
creditation standards include an obligation to participate 
in external quality assessment schemes. External quality 
assessment schemes have been shown to increase the ac-
curacy of genomic diagnostic testing  [36] .
 Incentives for Genomic Medicine 
 There will also be areas where genomic medicine could 
have a major impact on public health, but unfortunately 
traditional funding, pricing or reimbursement systems 
fail to provide enough incentives for test development. 
These areas include funding (a) the education of physi-
cians (such as genomics education) and increasing liter-
acy in genomics and genomics for patients and the gen-
eral public  [37, 38] , (b) allied professionals such as ge-
nomic counselors, and (c) rewarding/creating incentives 
to develop new tools that could revolutionize some thera-
peutic areas  [33] . It would be desirable to conduct a sur-
vey among clinicians in Europe to establish if there are 
any concerns with regard to drug-diagnostic companion 
products. This is further highlighted by the fact that many 
interviewed expert stakeholders disagreed about the role 
of clinicians  [4] . Some stakeholders reported that clini-
cians are most reluctant to adopt companion diagnostics 
even when funding is guaranteed, whereas others report-
ed that clinicians’ adoption is not a barrier to access at all 
 [39] . Whichever, close links between pathologists and cli-
nicians help to increase clinicians’ awareness about the 
kind of tests available and how these are appropriately 
used and interpreted. Furthermore, clinicians have an 
important impact on testing quality during the preanaly-
sis stage. Finally, close links are helpful when informal 
advice for patients is needed.
 On the other hand, patients rely traditionally on their 
doctors’ professional opinion and generally follow their 
advice. In recent decades, the clinician-patient relation-
ship has evolved into a partnership model. Indeed, in a 
recent survey, roughly 75% of European patients, par-
ticularly those of younger age, wished to play a more ac-
tive role in health-care decision-making  [40] . For these 
patients, it is crucial to have easy access to reliable infor-
mation about their own disease/condition, and treat-
ment options in clear and nontechnical language. This 
applies in particular to the complex field of genomic 
medicine.
 Fig. 3. Stages of the testing process and sources of variability inside and outside the genomic testing laboratory. 
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 Recommendation A : Further research should investi-
gate the knowledge and attitude of European clinicians 
towards genomic testing services.
 Reason : Clinicians are gatekeepers for patient access to 
drug-diagnostic companion products. In sharp contrast 
to their importance for patient access, comparatively little 
is known about the attitudes and behaviors of European 
physicians.
 Recommendation B : Collaboration between clinicians 
and pathologists in the area of genomic medicine should 
be increased.
 Reason: A survey of US clinicians revealed that one 
reason for not using pharmacogenomics is a lack of 
knowledge as to what tests are available, how to procure 
them, when to use them, how to interpret the results and 
how to apply them in the context of an individual patient 
 [41] . Similar results have also been forthcoming from Eu-
ropean countries  [42] . Furthermore, it has been shown 
that the preanalysis stage outside the laboratory is crucial 
for obtaining accurate test results. Increased collabora-
tion leads to an exchange of knowledge, lowers the thresh-
old to ask for advice and generates awareness about the 
available testing options.
 Conclusions and Future Perspectives 
 Genomic testing presents special challenges to pricing 
and reimbursement science because of the rapid evolu-
tion of new technologies and the lack of a clear under-
standing by all stakeholders of the requirements for inclu-
sion in coverage policies. Coverage for genomic tests has 
been a complicated issue, as no consensus exists as to 
what should be covered; thus, payers must consider op-
tions such as bundled payments or risk-sharing agree-
ments, so that genomic tests are accompanied by treat-
ment and an entire continuum of care. However, it is not 
known whether that would increase or decrease the up-
take of the offered test or how it would affect implemen-
tation  [43] .
 The implementation and the translation-expansion of 
research to model pricing and reimbursement policies 
would help to advance the field of genomic testing, setting 
an important precedent in a time of considerable ambigu-
ity, uncertainty and heterogeneity in genomic medicine 
policies.
 The main issue in this policy paper is to definitively 
show that patient outcomes and targeted therapies are de-
cisive in improving patient care and are far superior to the 
current hit-or-miss attempts currently practiced. This, 
plus proven pathway-based approach, defined precisely 
by the patient’s genotype information, will eventually be 
the most cost-effective approach to clinical practice, along 
with well-educated caretakers into this being the standard 
of care, hopefully then driving down costs. Then and only 
then will this approach become standardized by all, and 
not just at the major academic medical centers.
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